3SBio’s Amdokitug Wins NMPA Approval for Moderate-to-Severe Plaque Psoriasis
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (SHA: 688336), a subsidiary of 3SBio Inc. (HKG: 1530), announced that...
Bio-Thera’s Gotenfia Wins European Approval as Simponi Biosimilar
Bio-Thera Solutions Inc. (SHA: 688177) announced that the European Commission (EC) has approved Gotenfia (BAT2506), its...
First Imaging Raises $14.5 Million to Advance AI-Powered Intraoperative Imaging
First Imaging, a Nantong-based medical imaging equipment provider, has closed a Series B+ financing round...
CARsgen Therapeutics to Invest $54 Million in Shanghai CAR-T Manufacturing Facility
CARsgen Therapeutics Holdings Ltd. (HKG: 2171), a China-based CAR-T cell therapy specialist, announced plans to invest...
GSK Reports 7% Revenue Growth to $44.7 Billion in 2025; Oncology Surges 43%
GlaxoSmithKline plc (GSK, NYSE: GSK) delivered strong 2025 financial results, with total revenues rising 7% in...
Novocure’s Optune Pax Wins FDA Approval for Pancreatic Cancer; Zai Lab China Rights in Play
Novocure Ltd. (NASDAQ: NVCR), Zai Lab Ltd.’s (NASDAQ: ZLAB, HKG: 9688) Swiss oncology partner, announced FDA clearance for...
China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China
China Medical System Holdings Limited (HKG: 0867) announced a licensing agreement with Teikoku Seiyaku Co., Ltd.,...
Organon Reports 2025 Revenue Decline to $6.2 Billion; JADA Sale and Portfolio Pressures Weigh
Organon & Co. (NYSE: OGN) announced fourth quarter and full-year 2025 financial results, with total revenue...
Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise
Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294), a pioneer in cardiorenal metabolic syndrome treatment in China,...
Sanofi Appoints Belén Garijo as New CEO to Drive R&D Innovation and Productivity
Sanofi (NASDAQ: SNY) announced a leadership transition, with Paul Hudson stepping down as Chief Executive Officer...
Immunofoco Bio Files Hong Kong IPO for Solid Tumor CAR-T Pipeline
Shenzhen Immunofoco Biotechnology Co., Ltd., an innovative cell therapy developer, has submitted its IPO application...
Amgen’s UPLIZNA Wins European Approval for Generalized Myasthenia Gravis
Amgen Inc. (NASDAQ: AMGN) announced that the European Commission (EC) has approved UPLIZNA (inebilizumab) as an...
Innovent Biologics Initiates Phase 3 HeriCare-Breast01 Study for IBI354 in HER2+ Breast Cancer
Innovent Biologics, Inc. (HKG: 1801) announced first patient dosing in the pivotal Phase 3 HeriCare-Breast01 study...
Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals
Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) has entered a landmark licensing agreement with Madrigal...
Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion
Novartis AG (NYSE: NVS) has entered a long-term supply agreement with Niowave Inc., a US-based isotope...
Therom Fisher’s PPD Partners with Datavant to Integrate Real-World Data into Clinical Trials
Thermo Fisher Scientific Inc. (NYSE: TMO) announced a strategic partnership between its PPD clinical research business...
MSD’s Keytruda Wins FDA Approval for Platinum-Resistant Ovarian Cancer
Merck & Co. (MSD, NYSE: MRK) announced that the U.S. Food and Drug Administration (FDA) has...
Sanofi Invests $30 Million in GluBio’s Sickle Cell TPD Programs
GluBio Pharmaceutical Co., Ltd., a Zhejiang-based molecular glue targeted protein degradation (TPD) specialist, announced a...
Henlius Biotech Initiates Phase Ib/II Study for HLX43 ADC Combinations in Colorectal Cancer
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced first patient dosing in a Phase Ib/II clinical study...
Jingxin Pharmaceutical Files Hong Kong IPO for Dual Listing Strategy
Jingxin Pharmaceutical Co., Ltd. (SHE: 002020) has submitted its IPO prospectus to the Hong Kong Stock...